NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Closing the Gap: Death Rates in the Swiss HIV Cohort Study (SHCS) Compared to the Swiss Reference Population.

Jaggy C, Ledergerber B, von Overbeck J, Schwarz C, Baumgartner S, Rickenbach M, Furrer H, Telenti A, Battegay M, Flepp M, Vernazza P, Bernasconi E, Hirschel B; Conference on Retroviruses and Opportunistic Infections; Swiss HIV Cohort Study.

Abstr 10th Conf Retrovir Oppor Infect Feb 10 14 2003 Hynes Conv Cent Boston Mass USA Conf Retrovir Oppor Infect 10th 2003 Boston Mass. 2003 Feb 10-14; 10: abstract no. 917a.

SwissRe, Zurich

BACKGROUND: HAART has decreased AIDS deaths but mortality in patients with HIV is still perceived to be much higher than the mortality of the general population. This perception precludes life insurance.METHODS: Patients analyzed were all Swiss patients (29.1 percent women) with a SHCS visit after 1/1/1997. Prognostic factors examined were presence/absence of antibody to the hepatitis C virus, and success of treatment, defined as attaining, at least once, a CD4 count of > 250 after 1/1/1997, after more than 6 months on HAART. The analysis of mortality started with the date of the CD4 count indicating success in the successfully treated patients, and with the first cohort visit after 1/1/1997 in all others. Patients were followed until 12/31/2001, or until death, whatever occurred first. Official death registries were checked to determine if any of the patients in low-risk categories with loss of follow-up, had died. The excess death rate (EDR) of SHCS patients, in extra deaths per 1000 per year, was calculated on the basis of the most recentage-and-sex-specific Swiss population mortality.RESULTS: [table: see text] Conclusion: Succesfully treated HIV positive and hepC negative patients, including those who were immunosuppressed before treatment, have a short term mortality at least as low as successfully treated cancer patients (EDR in the range of 5 to 20) - a group who is able to obtain life insurance.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Insurance, Life
  • Population
  • Population Groups
  • economics
  • mortality
Other ID:
  • GWAIDS0021956
UI: 102261580

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov